# China Post-marketing Surveillance (PMS) Study of Fabrazyme®

> **NCT05054387** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 22 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Agalsidase beta

## Key facts

- **NCT ID:** NCT05054387
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-13
- **Primary completion:** 2023-03-09
- **Final completion:** 2023-03-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054387, "China Post-marketing Surveillance (PMS) Study of Fabrazyme®". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05054387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*